[8] Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol. 2023 Dec 8:S0923-7534(23)05104-9. doi: 10.1016/j.annonc.202...
[2]Chinese Society of Clinical Oncology CSCO.Breast Cancer Diagnosis and Treatment Guidelines 2021(in Chinese).Beijing:People’s Medical Publishing House,2021. [3]Cheng Y,Xiang H,Xin L,et al.Chinese Society of Breast Surgery(CSBrS),Chin...
参考来源:‘FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer’,新闻稿。Novartis;2024年9月17日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指导,请咨询主治医师。
原文出处：European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer 注：以上资讯来源于网络，由香港济民药业整理编辑（如有错漏，请帮忙指正），只为提供全球最新上市药品的资讯，帮助中国患者了解国际新药...
1. Seagen announces FDA accelerated approval of Tukysa (tucatinib) in combination with trastuzumab for people with previously treated RAS wild-type, HER2-positive metastatic colorectal cancer. News release. January 19, 2023. Accessed January 19, 2023. ...
原文出处:European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,...
原文出处:Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得...
When people in practice come up with those formerly-known-as-HER2-zero reports, how do they sort this out? How do they know if this patient might benefit from T-DXd? Esteva:That is a real issue in clinical practice because until the data with T-DXd were presented at ASCO in 2024, we...
原文出处:Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转...
4月21日,恒瑞医药宣布国家药品监督管理局批准公司自主研发的人表皮生长因子1/2/4(HER1/HER2/HER4)靶向药物吡咯替尼(艾瑞妮®)联合曲妥珠单抗和多西他赛用于HER2阳性晚期乳腺癌一线治疗,这是中国首个获批的受体酪氨酸激酶抑制剂(TKI)联合大分子抗体药物用于治疗晚期乳腺癌的双靶组合,为晚期乳腺癌患者带来用药新选择...